News | September 21, 2010

Counterclaim Filed in Patent Infringement Case

September 21, 2010 - Patent infringement claims by St. Jude Medical Systems against the Volcano Corporation are without merit, the company said Tuesday.

In a filing made in the United States District Court for the District of Delaware, Volcano denies allegations that its PrimeWire products infringe any valid claim of St. Jude's asserted patents. Furthermore, as described in detail in its answer, the company believes that two of the asserted St. Jude patents are unenforceable because they were obtained through acts of fraud on the United States Patent and Trademark Office (USPTO).

Specifically, Volcano believes that the individuals involved in securing these two patents knowingly withheld from the USPTO a patent describing the pioneering work of scientists at Volcano's predecessor company, Cardiometrics.

In addition, Volcano has alleged that St. Jude's PressureWire products and its RadiAnalyzer Xpress infringe three Volcano patents. In its counterclaim, Volcano is seeking injunctive relief and monetary damages. The company intends to demonstrate that St. Jude has adopted Volcano's technology to enable it to compete in the rapidly expanding sensor-equipped guidewire field.

"Volcano believes that it, not St. Jude or Radi Medical, has led the way in fractional flow reserve (FFR) technology by developing the first guide wires to incorporate a solid state pressure sensor, the WaveWire. Volcano's predecessor company was also the first to introduce a guide wire containing a solid-state sensor for measuring intravascular flow rates, the FlowWire. Volcano believes that the Cardiometrics patents and Volcano's related innovative products render St. Jude's asserted claims invalid," said Scott Huennekens, CEO of Volcano.

"As the innovator of these guide wire technologies, Volcano intends to set the historical record straight and will vigorously defend against St. Jude's claims. Volcano respects the intellectual property rights of its competitors and expects them do to the same," he added.

For more information please visit: www.volcanocorp.com

Related Content

One in Four Patients Have Residual Ischemia Following PCI
News | FFR Technologies | March 20, 2019
At the American College of Cardiology’s (ACC) annual meeting, March 16-18 in New Orleans, Philips announced the results...
HeartFlow Analysis Successfully Stratifies Heart Disease Patients at One Year
News | FFR Technologies | March 19, 2019
Late-breaking results confirm the HeartFlow FFRct (fractional flow reserve computed tomography) Analysis enables...
Abbott's Resting Full-cycle Ratio (RFR) intravascular diagnostic test is a newer type of fractional flow reserve (FFR) physiologic assessment. RFR is used to help identify significant narrowings of coronary arteries to determine the need for a stent or if a patient can be treated medically. Abbott FFR.

Abbott's Resting Full-cycle Ratio (RFR) intravascular diagnostic test is a newer type of fractional flow reserve (FFR) physiologic assessment. RFR is used to help identify significant narrowings of coronary arteries to determine the need for a stent or if a patient can be treated medically. 

Technology | FFR Technologies | March 06, 2019
March 5, 2019 –  The U.S.
CathWorks FFRangio System Receives U.S. FDA Clearance
Technology | FFR Technologies | December 21, 2018
CathWorks announced that its FFRangio System received U.S. Food  and Drug Administration (FDA) 510(k) clearance. The...
The late-breaking FAST-FFR Trial demonstrated that the sensitivity and specificity of the CathWorks FFRangio angiography imaging derived fractional flow reserve (FFR-angio) technology matched the performance of wire-based FFR measurements. #TCT2018

The late-breaking FAST-FFR Trial demonstrated that the sensitivity and specificity of the CathWorks FFRangio angiography imaging derived fractional flow reserve (FFR-angio) technology matched the performance of wire-based FFR measurements.

News | FFR Technologies | October 04, 2018
October 4, 2018 — The late-breaking FAST-FFR Trial demonstrated that the sensitivity and specificity of the CathWorks
SCAI and the European Society of Cardiology recently added iFR to their guidelines.

An illustration of Philip’s iFR technology, showing the iFR pressure readings and a fusion angio image indicating pressure drops in the vessel during wire pull back. SCAI and the European Society of Cardiology recently added iFR to their guidelines.

Feature | FFR Technologies | September 05, 2018 | Dave Fornell, Editor
The use of invasive, pressure wire-based fractional flow reserve (FFR) in the cath lab is now considered the gold sta
European Society of Cardiology Incorporates iFR Technology Into Updated Revascularization Guidelines
News | FFR Technologies | August 29, 2018
Philips announced that the European Society of Cardiology (ESC) has incorporated instantaneous wave-free ratio (iFR)...
iFR reference numbers posted for new users in the cath lab at Northwestern Medicine's Central DuPage Hospital in Winfield, Ill.
News | FFR Technologies | July 26, 2018
July 26, 2018 — The Society of Cardiac Angiography and Interventions (SCAI) released a focused update expert consensu
CathWorks Receives CPT Code for Non-invasive FFRangio Measurements During PCI
News | FFR Technologies | July 12, 2018
CathWorks announced the approval of a new Current Procedural Terminology (CPT) code 0523T for non-invasive, 3-D...
The ORBITA Trial showed FFR and iFR are good predictors of PCI outcomes. This was a 2018 PCR late-breaker.
News | FFR Technologies | May 29, 2018
May 29, 2018 — The first placebo-controlled trial that looked at how fractional flow reserve (FFR) and instantaneous
Overlay Init